Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Halaven
Eribulin is a microtubule dynamics inhibitor used in the treatment of certain types of breast cancer and liposarcoma. It belongs to the class of halichondrin B analogs and works by inhibiting the growth phase of microtubules without affecting the shortening phase, ultimately leading to cell cycle arrest and apoptosis. It is administered intravenously.
For the treatment of metastatic breast cancer and liposarcoma.
Outcome:
Increased eribulin exposure
Mechanism:
Reduced eribulin metabolism
Outcome:
Increased eribulin exposure
Mechanism:
Reduced eribulin metabolism
Outcome:
Potential increased risk of bleeding
Mechanism:
Additive effects on platelet function
Most likely new formulation: Eribulin nanoparticle delivery system (2025, 60% confidence)
Based on increasing usage in advanced breast cancer and liposarcoma, there is a 70% likelihood of expanded indications within the next 5 years.
Antineoplastic, Microtubule Inhibitor
Halichondrin B Analog